Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 26, 2024
Deals
Sarepta broadens pipeline via siRNA deal with Arrowhead, paying $825M up front
CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | May 17, 2024
Product Development
Vectorized antibodies are taking gene therapy beyond rare disease
ASGCT presentations showcase cancers, infectious diseases and chronic inflammatory conditions as potential applications of vectorized antibodies
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | Mar 23, 2024
Data Byte
EMA’s CHMP backs approval of Novartis’ complement drug
March decisions also include label extensions for UCB’s Bimzelx and Astellas’ Xtandi. Takeda pulls an application for Adcetris
BioCentury | Dec 12, 2023
Deals
Dec. 11 Quick Takes: BMS paying $800M up front for SystImmune’s bispecific ADC
Plus: Pain, hearing loss company Hoba raises €23M and more from Novartis, Cogent and Zafrens
BioCentury | Dec 7, 2023
Politics, Policy & Law
Dec. 6 Quick Takes: Pfizer CEO excoriates university presidents on antisemitism failure
Plus: J&J’s Duato: GLP-1 space ‘too crowded’ to enter, Pfizer leaving BIO and updates from Merck KGaA, Pharvaris, Novartis, Arvinas, Seagen, EyePoint and CatalYm
BioCentury | Oct 12, 2023
Product Development
Slimmed down Novartis is now poised to grow value, says CEO Narasimhan
How Vas Narasimhan is managing change as he continues to chart a new course for the pharma
BioCentury | Oct 2, 2023
Regulation
Oct. 2 Quick Takes: Takeda withdrawing Exkivity after confirmatory miss
Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen
BioCentury | Jun 12, 2023
Deals
Seeking high-value drugs, Novartis adds kidney franchise in $3.2B Chinook takeout
Biotech’s later-stage candidates give pharma two chances at a blockbuster, starting with IgA nephropathy indication amid rising competition
Items per page:
1 - 10 of 36